A Phase I, Open-Label, Multiple Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of RRx-001 in Subjects With Advanced Solid Tumors or Lymphomas For Which There Are No Currently Accepted Curative Therapies.

Trial Profile

A Phase I, Open-Label, Multiple Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of RRx-001 in Subjects With Advanced Solid Tumors or Lymphomas For Which There Are No Currently Accepted Curative Therapies.

Completed
Phase of Trial: Phase I

Latest Information Update: 19 Aug 2015

At a glance

  • Drugs RRx 001 (Primary)
  • Indications Lymphoma; Solid tumours
  • Focus Adverse reactions
  • Acronyms DINAMIC
  • Sponsors EpicentRx
  • Most Recent Events

    • 19 Aug 2015 Results published in Lancet Oncology, as per EpicentRx media release.
    • 18 Aug 2015 Results published in the Lancet Oncology.
    • 19 May 2015 Status changed from recruiting to completed as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top